Description: Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products. The Company operates through the segment of sales and marketing of pharmaceutical drugs developed by the Company or by its collaborative partners. Its products include tacrolimus immediate releaser, which is an immunosuppressive therapy used for the treatment and prevention of acute rejection following organ transplantation; Vistitan, which is a ophthalmology product; Topiramate extended-release (XR), which is a once-daily topiramate product designed for patient compliance, and Oxcarbazepine XR, which is a once-daily oxcarbazepine product. Its development-stage pipeline includes various products in neurology and psychiatry. Its lead development-stage product candidate is AQS-1301. In addition, the Company is developing a pipeline of other central nervous system product candidates. It has over two preclinical-stage programs and a clinical-stage program in development.
Home Page: www.aequuspharma.ca
AQS Technical Analysis
200 Granville Street
Vancouver,
BC
V6C 1S4
Canada
Phone:
604 336 7906
Officers
| Name | Title |
|---|---|
| Mr. Douglas Glen Janzen | Chairman, CEO & Pres |
| Ms. Ann Fehr CGA, CPA | CFO & Corp. Sec. |
| Mr. Stuart Fowler | Strategic Commercial Advisor & Independent Director |
| Mr. Grant Larsen | Chief Commercial Officer |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 24.3946 |
| Price-to-Sales TTM: | 1.7865 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |